At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 474 enrolled
Drug / intervention
Besifloxacin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.
In Brief
A Phase 3 clinical trial evaluating Besifloxacin and Vehicle (Placebo) for Bacterial Conjunctivitis. Completed, enrolled 474 participants across 1 site.
Detailed Summary
This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis. This study was conducted as a phase IIb study and continued with further enrollment as a phase III study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartOct 2009
Primary CompletionOct 2010
Study CompletionFeb 2011
TodayJul 2026
First PostedSep 9, 2009
Enrollment StartOct 1, 2009
Primary CompletionOct 1, 2010
Study CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.8 years ago
Interventions
Besifloxacindrug
Besifloxacin 0.6% administered into the study eye two times a day for three days.
Vehicle (Placebo)drug
Vehicle administered to the study eye two times a day for three days.